Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies that allows the creation of sensitive ass…
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-04-23 Financing
Sharp Therapeutics Corp. Closes Final Tranche of Note Offering and Enters into Letter Agreement for Potential Share Purchase
Material change report - English.pdf
Results 2026-04-17
SHARP THERAPEUTICS CORP. ANNOUNCES FOURTH QUARTER 2025 RESULTS, CLOSING OF CONVERTIBLE NOTE OFFERING AND ADOPTION OF SEMI-ANNUAL REPORTING
News release - English.pdf
Transactions 2026-04-17 Financing
Other material contracts - English.pdf
Results 2026-04-17
Annual information form - English.pdf
Results 2026-04-17
Annual MD&A - English.pdf
Results 2026-04-17
Audited annual financial statements – English.pdf
Transactions 2026-04-13 Financing
Sharp Therapeutics Corp. Closes Fourth Tranche of Private Placement for Aggregate Gross Proceeds of US$200,000
Material change report - English.pdf
News 2026-04-10
Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
News release - English.pdf
Transactions 2026-04-10 Financing
Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering
News release - English.pdf
Transactions 2026-04-07 Financing
Sharp Therapeutics Corp. Announces Closing of Third Tranche of Convertible Note Offering
Material change report - English.pdf
Transactions 2026-04-02 Financing
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
News release - English.pdf
News 2026-03-19
Report of Distributions outside Canada (Form 72-503F).pdf
Transactions 2026-03-19 Financing
Sharp Therapeutics Corp. Closes Second Tranche of Convertible Notes Offering
Material change report - English.pdf
Transactions 2026-03-13 Financing
Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering
News release - English.pdf
News 2026-03-06
Report of Distributions outside Canada (Form 72-503F).pdf
Transactions 2026-03-05 Financing
Sharp Therapeutics Corp. Closes First Tranche of Convertible Note Offering
Material change report - English.pdf
Transactions 2026-02-27 Financing
Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering
News release - English.pdf
Transactions 2026-02-05 Financing
Sharp Therapeutics Corp. Announces Proposed Non-Brokered Private Placement of Convertible Notes
Material change report - English.pdf
Transactions 2026-02-02 Financing
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
News release - English.pdf
Transactions 2025-12-19 Financing
Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options
News release - English.pdf
Results 2025-11-26
SHARP THERAPEUTICS CORP. REPORTS THIRD QUARTER 2025 RESULTS AND DEVELOPMENT UPDATE
News release - English.pdf
Results 2025-11-26 Financials
Interim MD&A - English.pdf
Results 2025-11-26 Financials
Interim financial statements/report – English.pdf
News 2025-10-18
Material change report - English.pdf
News 2025-10-14
News release - English.pdf
News 2025-08-29
News release - English.pdf
Results 2025-08-29 Financials
Interim MD&A - English.pdf
Results 2025-08-29 Financials
Interim financial statements/report – English.pdf
News 2025-07-29
News release - English.pdf
News 2025-07-21
News release - English.pdf
News 2025-06-18
Certificate re dissemination to shareholders.pdf